NetworkNewsBreaks – Xeris Pharmaceuticals Inc. (NASDAQ: XERS) Featured in Mizuho Securities Research Report
Xeris Pharmaceuticals Inc. (NASDAQ: XERS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Recent prescription trends of the overall glucagon market as well as Gvoke prefilled syringe turned more negative than our expectation due to COVID-19. This prompted us to do scenario analyses based on current trends. As a result, we are lowering our 2020 and 2021 revenue estimates from $11.9 MM and $60.9 MM to $5.4 MM and $41.1MM, respectively. However, we believe the long-term, ready-to-inject glucagon market opportunity has not changed, along with Xeris' relative competitive standing. As such,…







